CAMP RWE Trial: Amnion Grafts for Healing Hard-to-Heal Ulcers in RW Populations
A legfontosabb adatok
- Ki végzi
- Capsicure, LLC
- Hol
- Coral Gables, Houston, Indianapolis, Miami, Oxnard, St Louis és Syosset (Egyesült Államok)Mind a 7 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 165 fő, tervezett
- Kezdés
- 2025. okt. 1.
- Tervezett befejezés
- 2026. júl. 20.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
- A vizsgált kezelések
- IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap
- IP2: BioLab Tri-Membrane Wrap
- A regiszteradat frissítve
- 2025. október 22.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with a venous leg ulcer or diabetic foot ulcer that has not healed. It compares two amnion graft treatments.
- Életkor
- 18 years and older
- Nem
- Male or female
- A betegség stádiuma
- The venous leg ulcer or diabetic foot ulcer has lasted more than 4 weeks. It shrank by less than 50% in the last 4 weeks. The wound is at least 2 cm2 and at most 25cm2. If there is more than one wound, the largest one is studied.
- Korábbi kezelés
- No treatment of the wound with engineered tissue or other scaffold materials within 30 days before the first treatment visit.
A részvétel fő kizáró okai
- Pregnancy or breastfeeding, or able to become pregnant without proper birth control
- The wound shrank by 50% in the four weeks before joining
- Wound infection that needs local or whole-body antimicrobials or antibiotics
- Known reasons not to use amniotic tissue grafts
- Other health problems that the study doctor thinks may make the trial unsafe
A regiszter feltételei, szó szerint
Mind a 15 feltétel megnézéseKevesebb
Ki vehet részt
- Male or female 18 years of age and older
- 2. Subjects having a non-healing venous leg ulcer or diabetic foot ulcer of >4 weeks duration and visible signs of healing objectively, less than 50% reduction in wound size in the last 4 weeks
- Subjects' wound size is minimum of 2 cm2 and maximum of 25cm2
- If the subject has more than one eligible wound the largest wound will be selected (the index wound)
- Subject is able and willing to follow the protocol requirements
- Subject has signed informed consent
Ki nem vehet részt
- Visible signs of improvement in the four weeks before randomisation (defined objectively as a 50% reduction in surface area in the four weeks before enrolment)
- The subject has other concurrent conditions that in the opinion of the investigator may compromise subject safety
- The index ulcer shows clinical signs and symptoms of wound infection needing treatment with local or systemic antimicrobials or antibiotics
- Inability to adhere to the study protocol or study visit schedule
- Pregnancy
- Child-bearing potential without appropriate contraception
- Lactation
- Treatment of the wound with engineered tissue or other scaffold materials within 30 days preceding the first treatment visit
- Known contraindications to the use of amniotic tissue grafts
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- Solutions Medical ResearchCoral Gables, Egyesült ÁllamokContact: Liliana LorenzoRésztvevőt keres
- HOPE Vascular and PodiatryHouston, Egyesült ÁllamokContact: Mariana BurnierRésztvevőt keres
- Indiana University Health Methodist HospitalIndianapolis, Egyesült ÁllamokContact: Bryce HockmanRésztvevőt keres
- Nova Medical Services - Research Division LLCMiami, Egyesült ÁllamokContact: Valmys OrtizRésztvevőt keres
- Fomat Medical ResearchOxnard, Egyesült ÁllamokContact: Luis ParraRésztvevőt keres
- St. Louis Foot and Ankle, LLCSt Louis, Egyesült ÁllamokContact: Bonnie ScaggsRésztvevőt keres
- Jevlos Health, IncSyosset, Egyesült ÁllamokContact: Christopher InfantinoRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
CAMP RWE Trial: A Multicenter hybrid platform trial comparing the effects of a prospective cohort treated with a tri-layer amnion graft or a single layer amnion graft to a coarsened exact matched retrospective control cohort of patients with hard-to-heal DFUs and VLUs
A vizsgálat 3 csoportja
- Standard of CareNincs vizsgálati kezelés, összehasonlításként
This study will employ a platform umbrella design in which two studies will be run: one for diabetic foot ulcers and one for venous leg ulcers. Each study will have two intervention groups and one common SOC group. Subjects will be randomized to one of two interventions: IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap Subjects in the control group will be drawn from deidentified data sourced from the US Wound Registry. The US Wound Registry (USWR) is recognized by CMS as a Qualified Clinical Data Registry (QCDR). The matching of intervention to control groups will use coarsened exact matching (CSM) in which key variables are used to match: e.g., age, sex, baseline wound area, baseline wound age. The desired control subject pool should be three times larger than the prospective group (at least 165 in wound type.)
- IP1: BioLab Membrane Wrap LiteA vizsgált kezelés
This study will employ a platform umbrella design in which two studies will be run: one for diabetic foot ulcers and one for venous leg ulcers. Each study will have two intervention groups and one common SOC group. Subjects will be randomized to one of two interventions: IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap Subjects in the control group will be drawn from deidentified data sourced from the US Wound Registry. The US Wound Registry (USWR) is recognized by CMS as a Qualified Clinical Data Registry (QCDR). The matching of intervention to control groups will use coarsened exact matching (CSM) in which key variables are used to match: e.g., age, sex, baseline wound area, baseline wound age. The desired control subject pool should be three times larger than the prospective group (at least 165 in wound type.)
Kezelés: IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap
- IP2: BioLab Tri-Membrane WrapA vizsgált kezelés
This study will employ a platform umbrella design in which two studies will be run: one for diabetic foot ulcers and one for venous leg ulcers. Each study will have two intervention groups and one common SOC group. Subjects will be randomized to one of two interventions: IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap Subjects in the control group will be drawn from deidentified data sourced from the US Wound Registry. The US Wound Registry (USWR) is recognized by CMS as a Qualified Clinical Data Registry (QCDR). The matching of intervention to control groups will use coarsened exact matching (CSM) in which key variables are used to match: e.g., age, sex, baseline wound area, baseline wound age. The desired control subject pool should be three times larger than the prospective group (at least 165 in wound type.)
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Multicenter Hybrid Platform Trial Comparing the Effects of a Prospective Cohort Treated With a Tri- Layer Amnion Graft or a Single Layer Amnion Graft to a Coarsened Exact Matched Retrospective Control Cohort of Patients With Hard-to-heal DFUs and VLUs
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2025. október 22.